Media coverage
2
Media coverage
Title -Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis Media name/outlet M2 PressWIRE Country/Territory United States Date 11/12/24 Persons John Mascarenhas Title -Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis Media name/outlet ENP Newswire Country/Territory United Kingdom Date 11/12/24 Persons John Mascarenhas